NCT01537120View on ClinicalTrials.gov

Evaluation of Continuous Glucose Monitoring in Participants With Type 2 Diabetes Mellitus (MK-0000-258 AM2)

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Vildagliptin

DRUG

Placebo

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01537120 - Evaluation of Continuous Glucose Monitoring in Participants With Type 2 Diabetes Mellitus (MK-0000-258 AM2) | Biotech Hunter | Biotech Hunter